Pressure Surface denied for failing step therapy by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for pressure surface are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Applies Step Therapy to Pressure-Relieving Surfaces

Blue Cross Blue Shield plans often require a step-therapy ("fail-first") protocol for support surfaces, requiring that lower-cost or lower-specification surfaces — such as standard static overlays — be tried and documented as inadequate before a higher-specification powered or specialty surface will be covered. A step-therapy denial means the plan believes the required lower-tier surface has not yet been tried, or that adequate documentation of its failure has not been submitted.

## Why This Denial Is Appealable

Step-therapy protocols must yield to individual clinical circumstances. If the required lower-tier surface is clinically inappropriate for your wound stage, skin condition, or functional status, the prescriber can attest to that and request a step-therapy override. If the lower-tier surface was already tried — in the hospital, at a prior facility, or at home — and failed or was discontinued for clinical reasons, that history satisfies the step requirement regardless of whether it was billed through the current plan. Most states also have enacted step-therapy override laws that apply to fully-insured BCBS plans.

## Federal Appeal Framework

• Step-therapy override request: Many plans have a separate override pathway; submit it alongside or before the formal appeal. The override and appeal can proceed simultaneously.
• Internal appeal (ACA §2719): A step-therapy denial is an adverse benefit determination subject to at least one internal appeal. Request the specific step criteria in writing.
• State override protections: For fully-insured plans, check whether your state has enacted a step-therapy override law — many require approval within a defined number of days when clinical criteria are met.
• External review: After exhausting internal review, ACA §2719 external review is available. External reviewers apply clinical-appropriateness standards and regularly overturn step denials when prior failure is documented.
• Timeline: External review requests are typically due within four months of the final adverse internal decision. Expedited review is available when delay would endanger health.

## Documents to Gather

• Prior-surface trial records: Any documentation — hospital records, home-health notes, DME supplier records — establishing that lower-tier surfaces were used, including dates, duration, and the clinical outcome (wound progression, inadequate redistribution, skin breakdown).
• Clinical contraindication statement: If the lower-tier surface is clinically inappropriate without a prior trial, a prescriber letter explaining the specific clinical reasons (wound stage, condition complexity, risk factors) and referencing the applicable wound-care guideline organization.
• Current wound assessment: Objective clinical documentation of wound stage, measurements, and risk factors that support the need for the requested surface tier.
• BCBS step criteria: Obtain the exact step-therapy protocol from the BCBS policy. Confirm which specific surfaces are required as prior steps and what constitutes documented failure or contraindication.

## Criteria-Mapping Structure

For each required step in the BCBS protocol, create a table row: left column states the requirement verbatim; right column provides the specific chart entry, letter paragraph, or supplier record demonstrating that the step was completed or is clinically inappropriate. Address each step sequentially so the reviewer cannot identify any gap in the clinical narrative.